Hong Kong stocks slipped 35 points or 0.14% to 25,211 in early Tuesday trade, marking a fourth straight drop as U.S. futures softened ahead of a key central bank summit that could signal the path of U.S. interest rates. Sentiment remained fragile amid rising debt repayment risks in the city's property sector, with bond maturities projected to surge near 70% next year against a backdrop of falling sales. Tech and consumer names were broadly lower, as investors awaited the PBoC’s monthly loan prime rate review due Wednesday. In its quarterly report, the central bank signaled targeted support for the economy, suggesting restraint on aggressive easing despite July seeing China’s weakest month this year. Losses were offset by hopes of easing geopolitical tensions, as President Trump proposed a Putin–Zelensky meeting. Ascletis Pharma plunged 12% on a discounted share sale, while other pharma laggards included Sino Biopharma (-4.9%), Wuxi Biologics (-4.4%), CSPC (-3.3%), and Innovent (-2.5%).